Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver disease
Biotech
Arbor sails into rocky gene editing waters with $74M
The raise will support ABO-101, a CRISPR-based gene editing therapy for primary hyperoxaluria type 1 that is set to enter a phase 1 trial soon.
Darren Incorvaia
Mar 18, 2025 6:30am
Vertex axes Verve gene editing pact amid shift in R&D priorities
Feb 27, 2025 9:05am
Akero's stock doubles as midphase MASH trial hits the mark
Jan 27, 2025 8:31am
Galectin's stock halves after phase 3 MASH trial misses goal
Dec 20, 2024 2:40pm
Viking liver disease drug reduces fibrosis in final ph. 2 data
Nov 20, 2024 3:20pm
GSK’s itch prospect hits mark in phase 3 liver disease trial
Nov 19, 2024 8:24am
